Makers Laboratories Ltd (MAKERSL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Makers Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026
Financial Result · 04 Nov 2026, 5:56 pm
Makers Laboratories Reports Strong Turnaround in Q2 FY27 Consolidated Results Makers Laboratories reported a sharp consolidated turnaround for Q2 ended 30th Sep'26, posting revenue from operations of ₹4,821.01 lakh, up 41.07% YoY from ₹3,417.45 lakh. Consolidated net profit attributable to owners surged to ₹394.97 lakh compared to a net loss of ₹11.65 lakh in Q2 ended 30th Sep'25, driving diluted EPS to ₹6.69 from negative ₹0.20. Growth was largely propelled by chemical manufacturing, delivering ₹1,118.79 lakh in segment PBT. Standalone operations also turned profitable with net profit reaching ₹65.68 lakh versus a ₹31.19 lakh loss YoY.
Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026
Outcome · 04 Nov 2026, 5:51 pm
Makers Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) ■ Revenue: 4,821 (+41.1% YoY | +12.7% QoQ) ■ EBITDA: 1,210 (+429.3% YoY | +73.8% QoQ) ■ EBITDA Margin (%): 25.1 (+1841 bps YoY | +882 bps QoQ) ■ PAT: 395 (Loss to Profit YoY | +162.6% QoQ) ■ EPS (INR): 6.69 (Loss to Profit YoY | +162.4% QoQ) Makers Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) Segmental Performance Pharmaceutical ■ Revenue: 1,393 (+10.2% YoY | +35.7% QoQ) ■ EBIT: 36.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 2.6 (Loss to Profit YoY | Loss to Profit QoQ) Chemical Manufacturing ■ Revenue: 3,503 (+60.0% YoY | +5.8% QoQ) ■ EBIT: 1,119 (+402.1% YoY | +48.1% QoQ) ■ EBIT Margin (%): 31.9 (+2176 bps YoY | +913 bps QoQ)
Makers Laboratories Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 04 Nov 2026, 5:30 am
Makers Laboratories Schedules Board Meeting for Q2 and H1 Results Makers Laboratories Ltd. announced that its Board of Directors is scheduled to meet on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. Additionally, the trading window for dealing in company securities by insiders remains closed from 1st Oct'26 until 6th Nov'26, concluding 48 hours after the declaration of the financial results pursuant to SEBI insider trading regulations.
Credit Rating for Bank Facilities
Others (Uncategorized) · 01 Sept 2026, 11:42 pm
Makers Laboratories Credit Rating Reaffirmed by CARE On Sep 01, '26, CARE Edge Ratings reaffirmed the credit rating for Makers Laboratories' long-term bank facilities. The rating for the Rs. 8.00 crore facility remains 'CARE BBB+' with a 'Stable' outlook. This reaffirmation signals continued creditworthiness and financial stability for the company's existing debt obligations, which is a neutral to slightly positive signal for equity holders as it indicates no deterioration in the company's financial health from the rating agency's perspective.
Voting Results and Scrutinizer Report
Annual General Meeting · 07 Aug 2026, 10:17 pm
Makers Laboratories Shareholders Approve All Resolutions at 41st AGM At its 41st Annual General Meeting on 7th Aug'26, Makers Laboratories Ltd. shareholders approved all four ordinary resolutions by the requisite majority. Key approvals include the adoption of FY26 financial statements, the re-appointment of Mr. Saahil Parikh as Director, related party transactions with Ipca Laboratories Ltd., and the ratification of cost auditor remuneration for FY27. All resolutions received over 99% of votes in favor. Overall shareholder voting turnout was 62.5% of total outstanding shares.
41st Annual General Meeting of the Company
Annual General Meeting · 07 Aug 2026, 8:57 pm
Change in Directorship of Mr. Saahil Parikh from Wholetime Director to Non-Executive, Non-Independent Wholetime Director
Change in Management · 07 Aug 2026, 5:40 pm
Makers Labs Q1FY27 Loss Widens Amid CEO Transition Makers Laboratories reported a consolidated net profit of ₹150.43 Lacs for Q1FY27, up from ₹43.67 Lacs YoY, on revenue of ₹4,277.16 Lacs. Standalone net loss widened to ₹107.50 Lacs from ₹27.20 Lacs YoY. Concurrently, CEO Saahil Parikh will step down on 10th Aug'26 due to personal reasons. He will transition to a Non-Executive, Non-Independent Director role effective 11th Aug'26, subject to shareholder approval. The change ensures leadership continuity while marking a significant shift in the company's executive management structure.
Standalone and Consolidated Financial Results for Q1FY27
Financial Result · 07 Aug 2026, 5:36 pm
Makers Labs Q1FY27 Loss Widens Amid CEO Transition Makers Laboratories reported a consolidated net profit of ₹150.43 Lacs for Q1FY27, up from ₹43.67 Lacs YoY. However, on a QoQ basis, profit declined from ₹109.35 Lacs. Consolidated revenue rose to ₹4,277.16 Lacs from ₹3,500.10 Lacs YoY. Standalone operations posted a wider net loss of ₹107.50 Lacs versus a loss of ₹27.20 Lacs YoY. Concurrently, CEO Saahil Parikh will not seek reappointment after his term ends on 10 Aug’26, transitioning to a Non-Executive, Non-Independent Director role effective 11 Aug’26.
Outcome of Board Meeting
Outcome · 07 Aug 2026, 5:32 pm
Makers Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lacs) ■ Revenue: 4,277 (+22.2% YoY | +19.6% QoQ) ■ EBITDA: 696 (+131.1% YoY | +32.0% QoQ) ■ EBITDA Margin (%): 16.3 (+767 bps YoY | +153 bps QoQ) ■ PAT: 150 (+244.5% YoY | +37.6% QoQ) ■ EPS (INR): 2.55 (+244.6% YoY | +37.8% QoQ) Makers Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lacs) Segmental Performance Pharmaceutical ■ Revenue: 1,026 (-25.5% YoY | -9.2% QoQ) ■ EBIT: -126 (-319.7% YoY | -8.3% QoQ) ■ EBIT Margin (%): -12.3 (-1008 bps YoY | -198 bps QoQ) Chemical Manufacturing ■ Revenue: 3,312 (+54.0% YoY | +31.4% QoQ) ■ EBIT: 755 (+231.9% YoY | +28.1% QoQ) ■ EBIT Margin (%): 22.8 (+1222 bps YoY | -58 bps QoQ)
Makers Laboratories Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 07 Aug 2026, 5:30 am
Makers Laboratories to Announce Q1 FY27 Results on 7th Aug'26 Makers Laboratories has scheduled a Board of Directors meeting on 7th Aug'26 to consider and approve its Standalone and Consolidated Unaudited Financial Results for the first quarter ending 30th Jun'26. In connection with this, the trading window for insiders, which closed on 1st Jul'26, will remain shut until 9th Aug'26, 48 hours after the results are declared. This regulatory filing complies with SEBI's Listing Obligations and Disclosure Requirements. The company's Scrip Code on the BSE is 506919.
Intimation to shareholders regarding weblink of Annual Report
Annual Report · 13 Jul 2026, 8:31 pm
41st Annual General Meeting of the Company to be held on Friday, 7th August, 2026 at 12.30 p.m. through Video Conference
Annual General Meeting · 10 Jul 2026, 8:40 pm
Annual Report 2025-26
Others (Uncategorized) · 10 Jul 2026, 4:15 pm
Standalone and Consolidated Results for FY 25-26
Financial Result · 26 May 2026, 6:27 pm
Makers Laboratories Reports Q4 & FY26 Results, Standalone Loss and Consolidated Profit Makers Laboratories reported standalone results for the quarter ending 31st Mar'26, with revenue at ₹112.99 Cr and a net loss of ₹9.64 Cr, compared to a loss of ₹14.02 Cr YoY. For FY26, standalone revenue was ₹509.40 Cr, with a net loss of ₹17.20 Cr versus a profit of ₹46.41 Cr in FY25. Consolidated Q4FY26 revenue stood at ₹365.13 Cr with a net profit of ₹10.94 Cr. For FY26, consolidated revenue was ₹1,423.04 Cr and net profit was ₹23.51 Cr, down from ₹74.91 Cr in FY25.
Standalone and Consolidated Financial Results for FY 25-26
Outcome · 26 May 2026, 6:20 pm
Makers Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lacs) ■ Revenue: 3,575 (+5.5% YoY | +0.2% QoQ) ■ EBITDA: 527 (+71.0% YoY | +26.6% QoQ) ■ EBITDA Margin (%): 14.8 (+566 bps YoY | +307 bps QoQ) ■ PAT: 109 (Loss to Profit YoY | +16.6% QoQ) ■ EPS (INR): 1.85 (Loss to Profit YoY | +16.4% QoQ) Makers Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lacs) Segmental Performance Pharmaceutical ■ Revenue: 1,130 (+16.2% YoY | -11.1% QoQ) ■ EBIT: -116 (+41.1% YoY | -720.0% QoQ) ■ EBIT Margin (%): -10.3 (+999 bps YoY | -916 bps QoQ) Chemical Manufacturing ■ Revenue: 2,521 (+3.8% YoY | +8.3% QoQ) ■ EBIT: 589 (+44.5% YoY | +79.3% QoQ) ■ EBIT Margin (%): 23.4 (+659 bps YoY | +926 bps QoQ)
Makers Laboratories Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 26 May 2026, 5:30 am
Makers Laboratories to Announce Q4 & FY26 Results on 26th May'26 Makers Laboratories has scheduled a Board of Directors meeting on 26th May'26 to consider and approve the audited financial results for the fourth quarter and financial year ended 31st Mar'26. In connection with this, the trading window for insiders will remain closed from 1st Apr'26 until 28th May'26, which is 48 hours after the results are declared. This action complies with SEBI's Prohibition of Insider Trading Regulations.
Standalone and Consolidated Financial Results for 3rd quarter and nine months ended 31.12.2025
Financial Result · 10 Feb 2026, 6:51 pm
Makers Labs Q3FY26: Revenue Grows While Profitability Slides Makers Laboratories reported consolidated Q3FY26 results with revenue from operations at ₹3,566.76 lakhs, up 28.8% YoY. However, net profit attributable to owners was ₹93.76 lakhs, a significant decline from a loss of ₹29.67 lakhs YoY. Sequentially, revenue grew 4.4% QoQ while net profit recovered from a loss of ₹11.65 lakhs in Q2FY26. The Chemical Manufacturing segment drove revenue growth, while the Pharmaceutical segment posted a loss. For 9M FY26, net profit was ₹125.78 lakhs versus ₹753.60 lakhs YoY.
Standalone and Consolidated Financial Results for 3rd quarter and nine months ended 31.12.2025
Outcome · 10 Feb 2026, 6:47 pm
Makers Laboratories Limited - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) ■ Revenue: 3567 (+28.8% YoY | +4.4% QoQ) ■ EBITDA: 417 (+219.0% YoY | +82.2% QoQ) ■ EBITDA Margin (%): 11.7 (+696 bps YoY | +499 bps QoQ) ■ PAT: 93.8 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 1.59 (Loss to Profit YoY | Loss to Profit QoQ) Makers Laboratories Limited - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) Segmental Performance Pharmaceutical ■ Revenue: 1271 (+26.8% YoY | +0.5% QoQ) ■ EBITDA: -11.8 (+61.6% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -0.9 (+214 bps YoY | Profit to Loss QoQ) Chemical Manufacturing ■ Revenue: 2329 (+25.6% YoY | +6.4% QoQ) ■ EBITDA: -18.0 (+3.9% YoY | +68.3% QoQ) ■ EBITDA Margin (%): -0.8 (+24 bps YoY | +182 bps QoQ)
Re-lodgement of transfer requests report - November 2025 and December 2025
Others (Uncategorized) · 21 Jan 2026, 8:50 pm
Makers Labs Reports Nil Physical Share Transfer Requests for Nov-Dec'25 Makers Laboratories Ltd., on 21 Jan'26, submitted a report regarding the re-lodgement of physical share transfer requests for Nov'25 and Dec'25. As per the filing from its Registrar and Transfer Agent, MUFG Intime India, the company received "Nil" requests during this two-month period. Consequently, no requests were processed, approved, or rejected, confirming zero activity under the special window provided by the SEBI circular dated 2 Jul'25. This indicates minimal to no outstanding physical shareholding seeking transfer during this period.
Makers Laboratories Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 10 Feb 2026, 5:30 am
Makers Laboratories Sets Board Meeting for Q3 FY26 Results Makers Laboratories Ltd. has scheduled a Board of Directors meeting for 10th Feb'26. The agenda includes considering and approving the standalone and consolidated unaudited financial results for the third quarter and nine months ended 31st Dec'25. In connection with this, the trading window for insiders will remain closed from 1st Jan'26 until 12th Feb'26, which is 48 hours after the results are declared. This action complies with SEBI's insider trading regulations.
Re-lodgement of transfer requests of physical shares report - October 2025
Others (Uncategorized) · 18 Nov 2025, 9:46 pm
Standalone and Consolidated Financial Results for Q2 and half yea ended 30.09.2025
Financial Result · 07 Nov 2025, 5:58 pm
Standalone and Consolidated Financial Results for Q2 and half year ended 30.09.2025
Outcome · 07 Nov 2025, 5:53 pm
Makers Laboratories Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 07 Nov 2025, 5:30 am
Relodgement of transfer for physical shares - Sep 2025
Others (Uncategorized) · 10 Oct 2025, 10:43 pm